MY172729A - Pharmaceutical formulations - Google Patents
Pharmaceutical formulationsInfo
- Publication number
- MY172729A MY172729A MYPI2014000970A MYPI2014000970A MY172729A MY 172729 A MY172729 A MY 172729A MY PI2014000970 A MYPI2014000970 A MY PI2014000970A MY PI2014000970 A MYPI2014000970 A MY PI2014000970A MY 172729 A MY172729 A MY 172729A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical formulations
- formulations
- methylsulfonamido
- pyrazol
- propan
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563229P | 2011-11-23 | 2011-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172729A true MY172729A (en) | 2019-12-11 |
Family
ID=47501412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014000970A MY172729A (en) | 2011-11-23 | 2012-11-21 | Pharmaceutical formulations |
Country Status (38)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| CN103945831A (zh) | 2011-11-23 | 2014-07-23 | 诺华股份有限公司 | 医药制剂 |
| PT3302565T (pt) | 2015-06-04 | 2020-01-14 | Pfizer | Formas de dosagem sólida de palbociclib |
| RU2615986C1 (ru) * | 2016-02-25 | 2017-04-12 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| FI3463345T3 (fi) | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä | |
| CN106000220A (zh) * | 2016-06-30 | 2016-10-12 | 东华大学 | 一种含化学试剂的有机溶剂崩解片的制备方法与应用 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| WO2022074011A1 (en) | 2020-10-05 | 2022-04-14 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma |
| CN114181197B (zh) * | 2022-02-16 | 2022-05-06 | 北京康立生医药技术开发有限公司 | 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法 |
| TR2022009483A2 (tr) * | 2022-06-08 | 2023-12-21 | Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Palbosiklib içeren bir farmasötik bileşim. |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262137A1 (en) * | 2024-06-21 | 2025-12-26 | Nanoform Finland Oyj | Formulations comprising crystalline nanosized encorafenib |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5475888A (en) | 1977-11-29 | 1979-06-18 | Jiyasuko Kk | Surgical laser |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| WO1997008950A1 (en) | 1995-09-07 | 1997-03-13 | Fuisz Technologies, Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| EE9900527A (et) | 1997-05-22 | 2000-06-15 | G.D. Searle & Co. | Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| US6316435B2 (en) | 1999-02-24 | 2001-11-13 | Supergen, Inc. | Combination therapy for lymphoproliferative diseases |
| EP1239831B1 (en) | 1999-12-23 | 2012-10-31 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1456180B1 (en) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| US20090149469A1 (en) | 2004-01-09 | 2009-06-11 | Carlos Garcia-Echeverria | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors |
| JP4688876B2 (ja) | 2004-06-10 | 2011-05-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP5178515B2 (ja) | 2005-08-12 | 2013-04-10 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するピラゾール化合物 |
| EP1919460A2 (en) * | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| US20080242667A1 (en) | 2005-08-26 | 2008-10-02 | Smithkline Beecham Corporation | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| JP2009530261A (ja) | 2006-03-16 | 2009-08-27 | ファイザー・プロダクツ・インク | ピラゾール化合物 |
| WO2007123892A2 (en) | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| CA2663366C (en) | 2006-10-02 | 2012-02-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2008045627A2 (en) | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| US20090022789A1 (en) | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| CA2695114A1 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| CA2699301A1 (en) * | 2007-10-19 | 2009-04-23 | Abbott Gmbh & Co. Kg | Solid dispersion product of n-aryl urea-based drugs |
| US8785486B2 (en) | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| EA201001456A1 (ru) | 2008-03-21 | 2011-06-30 | Новартис Аг | Новые гетероциклические соединения и их применение |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK2324008T3 (da) | 2008-07-24 | 2012-07-23 | Nerviano Medical Sciences Srl | Diarylpyrazol som protein kinase inhibitorer |
| US8088771B2 (en) | 2008-07-28 | 2012-01-03 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene inhibitor compounds |
| CN102227421A (zh) | 2008-09-29 | 2011-10-26 | 贝林格尔.英格海姆国际有限公司 | 抗增殖化合物 |
| DK2346495T4 (da) * | 2008-10-07 | 2023-08-28 | Kudos Pharm Ltd | Farmaceutisk formulering 514 |
| WO2010056662A1 (en) | 2008-11-11 | 2010-05-20 | University Of Washington | Activated wnt-beta-catenin signaling in melanoma |
| WO2010070060A1 (en) | 2008-12-19 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| EP3045457B1 (en) | 2009-06-15 | 2018-05-09 | Nerviano Medical Sciences S.r.l. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| CN102947290B (zh) | 2010-01-27 | 2015-05-27 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
| SG184243A1 (en) | 2010-03-30 | 2012-10-30 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| EP2601185B1 (en) | 2010-08-03 | 2015-10-07 | Nerviano Medical Sciences S.r.l. | Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents |
| US20140093565A1 (en) | 2011-03-21 | 2014-04-03 | Valcuria Ab | A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof |
| US20140113919A1 (en) | 2011-06-14 | 2014-04-24 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| CN103945831A (zh) | 2011-11-23 | 2014-07-23 | 诺华股份有限公司 | 医药制剂 |
| RU2015121367A (ru) | 2012-11-08 | 2017-01-10 | Новартис Аг | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний |
-
2012
- 2012-11-21 CN CN201280056985.9A patent/CN103945831A/zh active Pending
- 2012-11-21 HU HUE12809882A patent/HUE040370T2/hu unknown
- 2012-11-21 ES ES12809882T patent/ES2695099T3/es active Active
- 2012-11-21 LT LTEP12809882.9T patent/LT2782557T/lt unknown
- 2012-11-21 CN CN201610104236.9A patent/CN105708819B/zh active Active
- 2012-11-21 UA UAA201403227A patent/UA115039C2/uk unknown
- 2012-11-21 EP EP18188984.1A patent/EP3449911B8/en active Active
- 2012-11-21 ES ES18188984T patent/ES3037966T3/es active Active
- 2012-11-21 KR KR1020147013457A patent/KR102091295B1/ko active Active
- 2012-11-21 PE PE2014000678A patent/PE20141994A1/es active IP Right Grant
- 2012-11-21 MY MYPI2014000970A patent/MY172729A/en unknown
- 2012-11-21 AR ARP120104373A patent/AR088936A1/es not_active Application Discontinuation
- 2012-11-21 JP JP2014543550A patent/JP6216325B2/ja active Active
- 2012-11-21 SI SI201231455T patent/SI2782557T1/sl unknown
- 2012-11-21 PL PL12809882T patent/PL2782557T3/pl unknown
- 2012-11-21 WO PCT/US2012/066185 patent/WO2013078264A1/en not_active Ceased
- 2012-11-21 AU AU2012340759A patent/AU2012340759C1/en active Active
- 2012-11-21 SG SG11201401260QA patent/SG11201401260QA/en unknown
- 2012-11-21 MX MX2014006278A patent/MX353446B/es active IP Right Grant
- 2012-11-21 DK DK12809882.9T patent/DK2782557T3/en active
- 2012-11-21 SM SM20180595T patent/SMT201800595T1/it unknown
- 2012-11-21 CA CA2856406A patent/CA2856406C/en active Active
- 2012-11-21 PT PT12809882T patent/PT2782557T/pt unknown
- 2012-11-21 EA EA201491007A patent/EA025389B1/ru unknown
- 2012-11-21 EP EP12809882.9A patent/EP2782557B1/en active Active
- 2012-11-21 HR HRP20181896TT patent/HRP20181896T1/hr unknown
- 2012-11-21 US US14/359,121 patent/US9387208B2/en active Active
- 2012-11-21 RS RS20181376A patent/RS58048B1/sr unknown
- 2012-11-21 BR BR112014011981A patent/BR112014011981B8/pt active IP Right Grant
- 2012-11-22 JO JOP/2012/0353A patent/JO3493B1/ar active
- 2012-11-22 TW TW101143808A patent/TWI649098B/zh active
-
2014
- 2014-04-02 ZA ZA2014/02418A patent/ZA201402418B/en unknown
- 2014-04-08 TN TNP2014000145A patent/TN2014000145A1/en unknown
- 2014-04-28 IL IL232305A patent/IL232305B/en active IP Right Grant
- 2014-04-28 CO CO14090466A patent/CO6940426A2/es unknown
- 2014-05-15 MA MA37033A patent/MA35716B1/fr unknown
- 2014-05-22 PH PH12014501157A patent/PH12014501157A1/en unknown
- 2014-05-22 CL CL2014001337A patent/CL2014001337A1/es unknown
- 2014-05-23 GT GT201400100A patent/GT201400100A/es unknown
-
2016
- 2016-06-10 US US15/179,190 patent/US9763941B2/en active Active
-
2017
- 2017-03-07 US US15/452,239 patent/US10258622B2/en active Active
- 2017-09-22 JP JP2017182214A patent/JP2018035171A/ja active Pending
-
2018
- 2018-03-14 US US15/921,306 patent/US10561654B2/en active Active
- 2018-11-20 CY CY20181101222T patent/CY1121421T1/el unknown
-
2023
- 2023-05-15 EC ECSENADI202334537A patent/ECSP23034537A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172729A (en) | Pharmaceutical formulations | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| MX2014007971A (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido. | |
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| PH12012502161A1 (en) | Pharmaceutical formulations comprising pioglitazone and linagliptin | |
| PH12014500987A1 (en) | Neprilysin inhibitors | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| MX392150B (es) | Moduladores de receptores canabinoides. | |
| MX2014006136A (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
| PL2771329T3 (pl) | Nowe związki di-podstawione 3,4-diamino-3-cyklobuteno- 1,2-dionu do zastosowania w leczeniu patologii, w których pośredniczą chemokiny | |
| EP3207928A4 (en) | Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| GEP201606566B (en) | Isoxazolidine derivatives | |
| EP2563785A4 (en) | Compounds as Agonists Against S1P1 Receptors | |
| EA201690673A1 (ru) | Комбинированная терапия лахинимодом для лечения рассеянного склероза | |
| EA201390619A1 (ru) | 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения | |
| TH171493A (th) | สูตรผสมทางเภสัชกรรม | |
| TH104292B (th) | สูตรผสมทางเภสัชกรรม | |
| MX2011003390A (es) | Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos. | |
| SA515360233B1 (ar) | مثبطات إنزيمات هستون ديميثيلاز |